Please select the option that best describes you:
Topics:
Radiation Oncology • Genitourinary Cancers
I am curious why the most recent NCCN guidelines (Version 4.2024, 05/17/24) omit the duration of ADT for high-risk prostate cancer patients.
It still lists 4-6 months for unfavorable intermediate risk, but I can't find the previously recommended "1.5-3 years" in the latest version.